Wakasugi H, Oshimi K, Miyata M, Morioka Y
J Clin Immunol. 1981 Jul;1(3):154-62. doi: 10.1007/BF00922757.
Recently, a streptococcal preparation, OK-432 has been used successfully as an immunopotentiator for immunotherapy in patients with malignant tumors in Japan. In this paper, we report that the administration of OK-432 augments the cytotoxic activity of peripheral blood lymphoid cells against a natural killer (NK) cell-sensitive erythroleukemic cell line, K562, in tumor patients. In patients before or after surgery, sufficient amounts of OK-432 strongly augmented the cytotoxic activity within 3 days after the initial administration of OK-432. Thereafter the levels of cytotoxicity declined rapidly. The administration of a lower dose of OK-432 gave a lower increase in cytotoxicity. Enhanced cytotoxicity occurred with the reintroduction of OK-432 but remained at lower levels of activity. Characterization and fractionation of OK-432-induced effector cells revealed that the augmented cytotoxicity seemed to be carried mainly by NK cells. A low titer of interferon was detected in 3 of 10 patients within 72 hr after the first inoculation of the agent. Furthermore, we discuss the potency of OK-432 for the induction of interferon in detail.
最近，一种链球菌制剂OK-432在日本已成功用作恶性肿瘤患者免疫治疗的免疫增强剂。在本文中，我们报告在肿瘤患者中，给予OK-432可增强外周血淋巴细胞对自然杀伤（NK）细胞敏感的红白血病细胞系K562的细胞毒活性。在手术前或手术后的患者中，足量的OK-432在首次给药后3天内可强烈增强细胞毒活性。此后，细胞毒性水平迅速下降。给予较低剂量的OK-432，细胞毒性的增加幅度较小。再次引入OK-432时细胞毒性增强，但活性水平仍较低。对OK-432诱导的效应细胞进行表征和分离显示，增强的细胞毒性似乎主要由NK细胞介导。在首次接种该制剂后72小时内，10名患者中有3名检测到低滴度的干扰素。此外，我们详细讨论了OK-432诱导干扰素的效力。
